Literature DB >> 22554450

Differences between opioids: pharmacological, experimental, clinical and economical perspectives.

Asbjørn M Drewes1, Rasmus D Jensen, Lecia M Nielsen, Joanne Droney, Lona L Christrup, Lars Arendt-Nielsen, Julia Riley, Albert Dahan.   

Abstract

Clinical studies comparing the response and side effects of various opioids have not been able to show robust differences between drugs. Hence, recommendations of the regulatory authorities have been driven by costs with a general tendency in many countries to restrict physician's use of opioids to morphine. Although this approach is recognized as cost-effective in most cases there is solid evidence that, on an individual patient basis, opioids are not all equal. Therefore it is important to have an armamentarium of strong analgesics in clinical practice to ensure a personalized approach in patients who do not respond to standard treatment. In this review we highlight differences between opioids in human studies from a pharmacological, experimental, clinical and health economics point of view. We provide evidence that individuals respond differently to opioids, and that general differences between classes of opioids exist. We recommend that this recognition is used to individualize treatment in difficult cases allowing physicians to have a wide range of treatment options. In the end this will reduce pain and side effects, leading to improved quality of life for the patient and reduce the exploding pain related costs.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22554450      PMCID: PMC3555047          DOI: 10.1111/j.1365-2125.2012.04317.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  137 in total

1.  Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model.

Authors:  Wolfgang Koppert; Harald Ihmsen; Nicole Körber; Andreas Wehrfritz; Reinhard Sittl; Martin Schmelz; Jürgen Schüttler
Journal:  Pain       Date:  2005-09-09       Impact factor: 6.961

2.  Lipophilicity of opioids determined by a novel micromethod.

Authors:  F Medzihradsky; P J Emmerson; C A Mousigian
Journal:  J Pharmacol Toxicol Methods       Date:  1992-04       Impact factor: 1.950

3.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

4.  Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network.

Authors:  Pål Klepstad; Stein Kaasa; Nathan Cherny; Geoffrey Hanks; Franco de Conno
Journal:  Palliat Med       Date:  2005-09       Impact factor: 4.762

5.  A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model.

Authors:  Camilla Staahl; Lona Louring Christrup; Søren Due Andersen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Pain       Date:  2006-04-04       Impact factor: 6.961

Review 6.  Human experimental pain models in drug development: translational pain research.

Authors:  Lars Arendt-Nielsen; Michele Curatolo; Asbjørn Drewes
Journal:  Curr Opin Investig Drugs       Date:  2007-01

7.  Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model.

Authors:  Camilla Staahl; Richard Upton; David J R Foster; Lona Louring Christrup; Kim Kristensen; Steen Honoré Hansen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  J Clin Pharmacol       Date:  2008-05       Impact factor: 3.126

Review 8.  Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.

Authors:  Davide Tassinari; Sergio Sartori; Emiliano Tamburini; Emanuela Scarpi; William Raffaeli; Paola Tombesi; Marco Maltoni
Journal:  J Palliat Med       Date:  2008-04       Impact factor: 2.947

9.  Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.

Authors:  Lars Arendt-Nielsen; Anne E Olesen; Camilla Staahl; Frédérique Menzaghi; Sherron Kell; Gilbert Y Wong; Asbjørn M Drewes
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892

10.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception.

Authors:  E E Codd; R P Shank; J J Schupsky; R B Raffa
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

View more
  43 in total

Review 1.  Evolving paradigms in the treatment of opioid-induced bowel dysfunction.

Authors:  Jakob Lykke Poulsen; Christina Brock; Anne Estrup Olesen; Matias Nilsson; Asbjørn Mohr Drewes
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

2.  Single-sweep spectral analysis of contact heat evoked potentials: a novel approach to identify altered cortical processing after morphine treatment.

Authors:  Tine M Hansen; Carina Graversen; Jens B Frøkjaer; Anne E Olesen; Massimiliano Valeriani; Asbjørn M Drewes
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

3.  Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.

Authors:  Ning-Sheng Cai; César Quiroz; Jordi Bonaventura; Alessandro Bonifazi; Thomas O Cole; Julia Purks; Amy S Billing; Ebonie Massey; Michael Wagner; Eric D Wish; Xavier Guitart; William Rea; Sherry Lam; Estefanía Moreno; Verònica Casadó-Anguera; Aaron D Greenblatt; Arthur E Jacobson; Kenner C Rice; Vicent Casadó; Amy H Newman; John W Winkelman; Michael Michaelides; Eric Weintraub; Nora D Volkow; Annabelle M Belcher; Sergi Ferré
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 14.808

Review 4.  Opioids and Chronic Pain: Where Is the Balance?

Authors:  Mellar P Davis; Zankhana Mehta
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

5.  Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.

Authors:  Philip Krieter; Shwe Gyaw; Roger Crystal; Phil Skolnick
Journal:  J Pharmacol Exp Ther       Date:  2019-04-02       Impact factor: 4.030

Review 6.  The switch from buprenorphine to tapentadol: is it worth?

Authors:  Adriana Miclescu
Journal:  Rom J Anaesth Intensive Care       Date:  2016-10

Review 7.  Updates in palliative care - overview and recent advancements in the pharmacological management of cancer pain.

Authors:  Helen Wood; Andrew Dickman; Angela Star; Jason W Boland
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

8.  Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor-β Signaling, Not μ-Opioid Receptor Internalization.

Authors:  S Puig; K E Barker; S R Szott; P T Kann; J S Morris; H B Gutstein
Journal:  Mol Pharmacol       Date:  2020-07-28       Impact factor: 4.436

Review 9.  Pharmacological pain management in chronic pancreatitis.

Authors:  Søren S Olesen; Jacob Juel; Carina Graversen; Yuri Kolesnikov; Oliver H G Wilder-Smith; Asbjørn M Drewes
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

10.  Calabadion 1 selectively reverses respiratory and central nervous system effects of fentanyl in a rat model.

Authors:  Tharusan Thevathasan; Stephanie D Grabitz; Peter Santer; Paul Rostin; Oluwaseun Akeju; James D Boghosian; Monica Gill; Lyle Isaacs; Joseph F Cotten; Matthias Eikermann
Journal:  Br J Anaesth       Date:  2020-03-30       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.